ASH24 studies from MD Anderson presented by Jayastu Senapati
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X:
“ASH24 starts this week!
Excited to attend the annual scientific extravaganza and interact with friends, colleagues, collaborators and industry at San Diego.
Happy to present the following studies from MD Anderson Cancer Center at ASH24.
Check them out if you are interested in AML/ALL.
1. FLAG-GO leads to high frequency of optimal PCR responses and RFS than FLAG-IDA in CBF-AML: 200 patient long-term FU data of an ongoing phase 2 study, Gautam Borthakur.
2. Cohesin complex genes (SMC1A, SMC3, STAG1/2, RAD21) mutated AML respond favorably to venetoclax based therapy: Large retrospective analysis, Naval Daver.
3. Combination of CPX-351 and Gemtuzumab Ozogamicin in Relapsed Refractory Acute Myeloid Leukemia and Post Hypomethylating Agent Failure High-Risk Myelodysplastic Syndrome: Pilot study, Jazz Pharmaceuticals.
4. Treated Secondary AML (AML in patients with prior MDS, MDS/MPN overlap syndromes and treated with HMA/chemo/allo-HSCT): independent high-risk AML subtype (irrespective of genomics) with dismal outcomes, Tapan Kadia.
5. Final update of the phase 1b/2 Azacitidine-Venetoclax-Magrolimab study in newly diagnosed and R/R AML: Clinical and correlative data, Naval Daver, Hussein Abbas, Sanam Loghavi.
6. 10-Year follow up data of Mini-HyperCVD-InO +/- Blina as frontline therapy in older patients with Ph-ve B-cell ALL: 5 year PFS 46%, OS 50%, CRD 79%, Hagop Kantarjian, Elias Jabbour.
7. Chemotherapy free regimen of InO+Blina as frontline therapy in older patients (>70 years or 60-70 with poor PS) with Ph-ve B-cell ALL: 1 year PFS 64%, OS 70%, CRD 73%, Hagop Kantarjian, Elias Jabb.
8. Impact of myeloid type mutations in adult patients with Ph-ve B-cell treated with InO and/or Blina containing frontline therapy, Elias Jabbour, MD Anderson Cancer Centre.
AML with primary induction failure: Outcomes with AlloHSCT.”
Jayastu Senapati, an Assistant Professor of Leukemia at MD Anderson Cancer Center, specializes in hematology. He has been honored with several awards, including the ASCO Conquer Cancer Merit Award in 2022 and 2023, and the ASH Abstract Achievement Award in 2023, among many others.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023